SELLAS Life Sciences (SLS) Current Deferred Revenue (2011 - 2021)
SELLAS Life Sciences' (SLS) quarterly Current Deferred Revenue came in at $900000.0 in Q1 2021, down 83.93% on a QoQ basis from $5.6 million in Q4 2020.
SELLAS Life Sciences (SLS) Current Deferred Revenue (2011 - 2021) Analysis & Trends
SELLAS Life Sciences (SLS) has 3 years of Current Deferred Revenue data on file, last reported at $900000.0 in Q1 2021.
- On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $900000.0 in Q1 2021; TTM through Mar 2021 was $900000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $5.6 million, changed N/A from the prior year.
- Current Deferred Revenue for Q1 2021 stood at $900000.0, down from $5.6 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for SLS reached as high as $5.6 million in Q4 2020 and fell as low as $900000.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | SELLAS Life Sciences | 3.23 Mn | 3.23 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 900,000.00 |
| Dec 31, 2020 | 5.60 Mn |
| Dec 31, 2011 | 816,000.00 |
| Sep 30, 2011 | 877,000.00 |
| Jun 30, 2011 | 578,000.00 |